1. Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. (4th November 2015) Authors: Schaer, David; Li, Yanxia; Castaneda, Stephen; Inigo, Ivan; Surguladze, David; Xu, Xiaohong; Nugent, Desiree; Murphy, Mary; Hall, Gerald; Benhadji, Karim; Guba, Susan; Li, Yiwen; Kalos, Michael; Driscoll, Kyla Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment. (6th November 2014) Authors: Budhu, Sadna; Schaer, David; Li, Yongbiao; Houghton, Alan; Silverstein, Samuel; Merghoub, Taha; Wolchok, Jedd D Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment. (6th November 2014) Authors: Zappasodi, Roberta; Budhu, Sadna; Schaer, David; Yang, Xia; Zhong, Hong; Merghoub, Taha; Wolchok, Jedd D Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment. (7th November 2013) Authors: Budhu, Sadna; Schaer, David; Li, Yongbiao; Houghton, Alan; Silverstein, Samuel; Merghoub, Taha; Wolchok, Jedd Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Issue 2 (December 2015) Authors: Schaer, David; Li, Yanxia; Castaneda, Stephen; Inigo, Ivan; Surguladze, David; Xu, Xiaohong; Nugent, Desiree; Murphy, Mary; Hall, Gerald; Benhadji, Karim; Guba, Susan; Li, Yiwen; Kalos, Michael; Driscoll, Kyla Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. (2nd July 2016) Authors: Holmgaard, Rikke B.; Brachfeld, Alexandra; Gasmi, Billel; Jones, David R.; Mattar, Marissa; Doman, Thompson; Murphy, Mary; Schaer, David; Wolchok, Jedd D.; Merghoub, Taha Journal: Oncoimmunology Issue: Volume 5:Number 7(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗